View ORCID ProfileTommaso Ballarini, Debora Melo van Lent, Julia Brunner, Alina Schröder, Steffen Wolfsgruber, Slawek Altenstein, View ORCID ProfileFrederic Brosseron, Katharina Buerger, Peter Dechent, Laura Dobisch, Emrah Düzel, Birgit Ertl-Wagner, Klaus Fliessbach, Silka Dawn Freiesleben, View ORCID ProfileIngo Frommann, Wenzel Glanz, Dietmar Hauser, John Dylan Haynes, Michael T. Heneka, Daniel Janowitz, Ingo Kilimann, Christoph Laske, Franziska Maier, Coraline Danielle Metzger, Matthias H. Munk, View ORCID ProfileRobert Perneczky, Oliver Peters, Josef Priller, View ORCID ProfileAlfredo Ramirez, Boris-Stephan Rauchmann, Nina Roy, View ORCID ProfileKlaus Scheffler, Anja Schneider, Annika Spottke, Eike Jakob Spruth, Stefan J. Teipel, Ruth Vukovich, Jens Wiltfang, Frank Jessen, View ORCID ProfileMichael Wagner, on behalf of the DELCODE Study GroupFirst published May 5, 2021, DOI: https://doi.org/10.1212/WNL.0000000000012067
Objective To determine whether following a Mediterranean-like diet (MeDi) relates to cognitive functions and in vivo biomarkers for Alzheimer disease (AD), we analyzed cross-sectional data from the German DZNE-Longitudinal Cognitive Impairment and Dementia Study.
Method The sample (n = 512, mean age 69.5 ± 5.9 years) included 169 cognitively normal participants and individuals at higher AD risk (53 with relatives with AD, 209 with subjective cognitive decline, and 81 with mild cognitive impairment). We defined MeDi adherence according to the food frequency questionnaire. Brain volume outcomes were generated via voxel-based morphometry on T1-MRI, and cognitive performance was assessed with an extensive neuropsychological battery. AD-related biomarkers (β-amyloid42/40 [Aβ42/40] ratio, phosphorylated tau 181 [pTau181]) in CSF were assessed in n = 226 individuals. We analyzed the associations between MeDi and outcomes with linear regression models controlling for several covariates. In addition, we applied hypothesis-driven mediation and moderation analysis.
Results Higher MeDi adherence related to larger mediotemporal gray matter volume (p < 0.05 family-wise error corrected), better memory (β ± SE = 0.03 ± 0.02; p = 0.038), and less amyloid (Aβ42/40 ratio, β ± SE = 0.003 ± 0.001; p = 0.008) and pTau181 (β ± SE = −1.96 ± 0.68; p = 0.004) pathology. Mediotemporal volume mediated the association between MeDi and memory (40% indirect mediation). Finally, MeDi favorably moderated the associations among Aβ42/40 ratio, pTau181, and mediotemporal atrophy. Results were consistent correcting for APOE-ε4 status.
Conclusion Our findings corroborate the view of MeDi as a protective factor against memory decline and mediotemporal atrophy. They suggest that these associations might be explained by a decrease of amyloidosis and tau pathology. Longitudinal and dietary intervention studies should further examine this conjecture and its treatment implications.
You can read the full article at Neurology.org
